Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANB019 single-arm multiple-dose study in generalized pustular psoriasis
2017-004021-33Phase 2Unknown
- Sponsor
- AnaptysBio, Inc.
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imsidolimab in generalized pustular psoriasis (GPP), sponsored by AnaptysBio, Inc. Primary endpoints: Proportion of subjects achieving clinical response at Week 4 and Proportion of subjects achieving clinical response at Week 16. Status: unknown.
02
Drugs
imsidolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on 2017-004021-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004021-33.